# Phase 2 Non-Muscle Invasive Bladder: 26 recruiting (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 26 trials in phase 2 for Non-Muscle Invasive Bladder Neoplasms that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Non-Muscle Invasive Bladder Neoplasms trials: 26 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/non-muscle-invasive-bladder-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 26
- Recruiting or not yet: 26
- Read on: November 19, 2026

## Trials

The 25 newest of 26, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 8, 2026 | NCT07808216 | Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT | Tianjin First Central Hospital | Phase 2 | Not yet recruiting | Non Muscle Invasive Bladder Cancer | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808216) |
| August 20, 2026 | NCT07777848 | A Study to Evaluate the Efficacy and Safety of RAG-01 as Monotherapy and in Combination With Chemotherapy in Patients With Non-muscle... | Ractigen Therapeutics. | Phase 2 | Not yet recruiting | Non-muscle Invasive Bladder Cancer (NMIBC) | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07777848) |
| August 5, 2026 | NCT07747740 | Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer | Blokhin's Russian Cancer Research Center | Phase 2 | Recruiting | Non-Muscle-Invasive Bladder Cancer, BCG-Unresponsive Bladder Cancer | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07747740) |
| June 12, 2026 | NCT07646145 | Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer | Shanxi Province Cancer Hospital | Phase 2 | Recruiting | Non-Muscle-Invasive Bladder Cancer (NMIBC) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07646145) |
| June 4, 2026 | NCT07625527 | Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable... | Tianjin Medical University Second Hospital | Phase 2 | Recruiting | Bladder (Urothelial, Transitional Cell) Cancer, Non Muscle Invasive Bladder Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625527) |
| January 7, 2026 | NCT07322263 | Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC | Sponsor not shown (see the record) | Phase 2 | Recruiting | Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade... | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07322263) |
| December 16, 2025 | NCT07283835 | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin | Lepu Biopharma Co., Ltd. | Phase 2 | Recruiting | Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283835) |
| September 24, 2025 | NCT07189793 | Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase... | First Affiliated Hospital of Wenzhou Medical University | Phase 2 | Not yet recruiting | Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder, Non-Muscle-Invasive Bladder... | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189793) |
| August 3, 2025 | NCT07100184 | RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients | Peking University First Hospital | Phase 2 | Not yet recruiting | HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07100184) |
| June 13, 2025 | NCT07019220 | Chemoablation for Low-Grade Bladder Cancer | Sponsor not shown (see the record) | Phase 2 | Recruiting | Bladder (Urothelial, Transitional Cell) Cancer | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07019220) |
| May 29, 2025 | NCT06995677 | Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | Tyra Biosciences, Inc | Phase 2 | Recruiting | Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, FGFR3 Gene... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06995677) |
| May 15, 2025 | NCT06972615 | Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy | Sponsor not shown (see the record) | Phase 2 | Recruiting | Non Muscle Invasive Bladder Cancer | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06972615) |
| February 18, 2025 | NCT06833073 | A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | Merck Sharp & Dohme LLC | Phase 2 | Recruiting | Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ | 308 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06833073) |
| February 17, 2025 | NCT06829823 | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | ImmunityBio, Inc. | Phase 2 | Not yet recruiting | Non-muscle Invasive Bladder Cancer (NMIBC) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06829823) |
| December 13, 2024 | NCT06733363 | A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder... | Roswell Park Cancer Institute | Phase 2 | Recruiting | Non-Muscle Invasive Bladder Carcinoma, Recurrent Bladder Carcinoma, Recurrent Non-Muscle Invasive Bladder Carcinoma... | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06733363) |
| October 29, 2024 | NCT06663137 | A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC | Relmada Therapeutics, Inc. | Phase 2 | Recruiting | Non Muscle Invasive Bladder Cancer | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06663137) |
| October 8, 2024 | NCT06630871 | A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of... | Fujian Medical University Union Hospital | Phase 2 | Not yet recruiting | NMIBC | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06630871) |
| July 16, 2024 | NCT06503614 | A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer | Sponsor not shown (see the record) | Phase 2 | Recruiting | Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06503614) |
| March 15, 2024 | NCT06310369 | Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 | Not yet recruiting | Bladder Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06310369) |
| January 26, 2024 | NCT06227065 | Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids | Hospital Centre Biel/Bienne | Phase 2 | Not yet recruiting | Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low Grade | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06227065) |
| July 18, 2023 | NCT05951179 | Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | Protara Therapeutics | Phase 2 | Recruiting | Non-muscle Invasive Bladder Cancer | 131 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05951179) |
| July 13, 2023 | NCT05943379 | RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects | RemeGen Co., Ltd. | Phase 2 | Recruiting | NMIBC | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05943379) |
| April 3, 2023 | NCT05796375 | Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance | White River Junction Veterans Affairs Medical Center | Phase 2 | Recruiting | Non-muscle-invasive Bladder Cancer | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05796375) |
| April 14, 2022 | NCT05327647 | A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer | CHU de Quebec-Universite Laval | Phase 2 | Recruiting | Non-Muscle Invasive Bladder Cancer | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05327647) |
| May 10, 2019 | NCT03945162 | Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients | Theralase® Technologies Inc. | Phase 2 | Recruiting | Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03945162) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Roswell Park Cancer Institute | 1 |
| Shanxi Province Cancer Hospital | 1 |
| [RemeGen Co., Ltd.](https://specstream.ai/data/clinical-trials/company/remegen-co-ltd) | 1 |
| CHU de Quebec-Universite Laval | 1 |
| Protara Therapeutics | 1 |
| Ractigen Therapeutics. | 1 |
| Tianjin Medical University Second Hospital | 1 |
| White River Junction Veterans Affairs Medical Center | 1 |
| Lepu Biopharma Co., Ltd. | 1 |
| Peking University First Hospital | 1 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Tianjin First Central Hospital | 1 |
| Relmada Therapeutics, Inc. | 1 |
| First Affiliated Hospital of Wenzhou Medical University | 1 |
| Tyra Biosciences, Inc | 1 |
| Hospital Centre Biel/Bienne | 1 |
| Fujian Medical University Union Hospital | 1 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| [ImmunityBio, Inc.](https://specstream.ai/data/clinical-trials/company/immunitybio-inc) | 1 |
| Blokhin's Russian Cancer Research Center | 1 |
| Theralase® Technologies Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 8 |
| China | 7 |
| Canada | 4 |
| Argentina | 3 |
| Brazil | 2 |
| Australia | 2 |
| Italy | 2 |
| Netherlands | 2 |
| Spain | 2 |
| Japan | 1 |
| Taiwan | 1 |
| Ukraine | 1 |
| Chile | 1 |
| Colombia | 1 |
| Denmark | 1 |
| France | 1 |
| Germany | 1 |
| Greece | 1 |
| Hungary | 1 |
| Peru | 1 |
| Poland | 1 |
| Thailand | 1 |
| United Kingdom | 1 |
| Israel | 1 |
| Switzerland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Salad bars in the United States](https://specstream.ai/data/businesses/salad-bars/united-states)
- [Vascular medicine practices in the United States](https://specstream.ai/data/businesses/vascular-medicine-practices/united-states)
- [B2B newspaper advertising companies in the United States](https://specstream.ai/data/businesses/b2b-newspaper-advertising-companies/united-states)
- [Colleges and universities in the United States](https://specstream.ai/data/businesses/colleges-and-universities/united-states)
- [Farm equipment suppliers in the United States](https://specstream.ai/data/businesses/farm-equipment-suppliers/united-states)
- [Inspection companies in the United States](https://specstream.ai/data/businesses/inspection-companies/united-states)
